Soluble oligomeric Aβ disrupts the protein kinase C signaling pathway

NeuroReport

Volumn 15, Issue 3, 2004, Pages 503-507

  Kim, Hyeon Jin ^a   Kim, Jeong Hak ^a   Chae, Soo Cheon ^b   Park, Yeong Chul ^c   Kwon, Keun Sang ^d   Hong, Seong Tshool ^d  

^a Jinis Inc   (South Korea)

^b Wonkwang University   (South Korea)

^c Catholic University of Daegu   (South Korea)

^d Chonbuk National University Medical School   (South Korea)

Author keywords

Alzheimer's disease; Oligomeric A ; Phosphorylation; PKC; Signaling

Indexed keywords

AMYLOID BETA PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; MEMBRANE ENZYME; MONOMER; OLIGOMER; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INACTIVATION; EVOKED RESPONSE; MOUSE; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLUBILITY; TIME; ANIMAL; BRAIN TUMOR; CELL SURVIVAL; DRUG EFFECT; METABOLISM; NEUROBLASTOMA; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

AMYLOID BETA-PROTEIN; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOSOL; MICE; NEUROBLASTOMA; PROTEIN KINASE C; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES;

EID: 1542327573     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200403010-00024     Document Type: Article

References (21)

1. Cummings JL, Vinters HV, Cole GM and Khachaturian ZS. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 51, S2-17 (1998).
2. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-766 (2001).
3. Glenner GC and Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120, 885-890 (1984).
4. Hardy J and Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185 (1992).
5. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG and Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13, 1676-1687 (1993).
6. Lorenzo A and Yankner BA. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 91, 12243-12247 (1994).
7. Atwood CS, Martins RN, Smith MA and Perry G. Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. Peptides 23, 1343-1350 (2002).
8. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96, 3228-3233 (1999).
9. Swaab DF, Lucassen PJ, Salehi A, Scherder EJ, van Someren EJ and Verwer RW. Reduced neuronal activity and reactivation in Alzheimer's disease. Prog Brain Res 117, 343-377 (1998).
10. Kirkitadze MD, Condron MM and Teplow DB. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J Mol Biol 312, 1103-1119 (2001).
11. Ashe KH. Learning and memory in transgenic mice modeling Alzheimer's disease. Learn Mem 8, 301-308 (2001).
12. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ and Beyreuther K. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46, 860-866 (1999).
13. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
14. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155, 853-862 (1999).
15. Hardy J and Gwinn-Hardy K. Genetic classification of primary neurodegenerative disease. Science 282, 1075-1079 (1998).
16. Kim HJ, Chae SC, Lee DK, Chromy B, Lee SC, Park YC et al. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J 17, 118-120 (2003).
17. Swaab DF, Lucassen PJ, vande Nes JAP, Ravid R and Salehi A. Reduced neuronal activity is one of the major hallmarks of Alzheimer's disease. In: Hyman BT, Duyckaerts C and Christen Y (eds). Connections, Cognition and Alzheimer's Disease. Springer-Verlag; 1997, pp. 83-104.
18. Bobinski M, de Leon MJ, Tarnawski M, Wegiel J, Bobinski M, Reisberg B et al. Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Brain Res 805, 267-269 (1998).
19. Tanaka C and Nishizuka Y. The protein kinase C family for neuronal signaling. Annu Rev Neurosci 17, 551-567 (1994).
20. Rossner S, Mendla K, Schliebs R and Bigl V. Protein kinase C alpha and beta1 isoforms are regulators of alpha-secretory proteolytic processing of amyloid precursor protein in vivo. Eur J Neurosci 13, 1644-1648 (2001).
21. Lanius RA, Wagey R, Sahl B, Beattie BL, Feldman H, Pelech SL et al. Protein kinase C activity and protein levels in Alzheimer's disease. Brain Res 764, 75-80 (1997).